Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As we grew our portfolio, we also built a strong, experienced and dedicated R&D organization, ready to take on new opportunities as we continue to build our existing portfolio with new assets via business development |
| As you heard from us this morning, our strong execution in 2023 and solid momentum going into this year positions Harmony well for continued growth in 2024 |
| Harmony continues to be a growth story as demonstrated by our team's accomplishments throughout 2023 |
| We delivered another strong year of performance across the organization, growing revenue and average number of patients on WAKIX |
| And I think we're very excited about the potential if successful to bring a non-scheduled treatment option given what we've seen the impact of narcolepsy on these individuals' lives |
| All of this reflects momentum across our organization from our commercial business with WAKIX in narcolepsy to our clinical development programs, as well as positive interactions with FDA related to these programs |
| I think obviously, positive signals from the agency on the importance of that indication in pediatric narcolepsy patients |
| But I think though the takeaway is we're extremely pleased with what we're seeing, confident continued growth and we really believe that WAKIX is well positioned for future growth in ‘24 |
| I am very excited for the year ahead and believe that Harmony is poised to accelerate our growth in 2024 |
| And then typically in previous years, we expect to have the traditional tailwinds in the second and the fourth quarter with stronger prescription demand again |
| This result demonstrates the significant underlying demand for WAKIX and the durability of the brand going into year five in the market |
| Other factors that drive our confidence in our ability to grow WAKIX include its meaningfully differentiated product profile, which results in its broad clinical utility, couple that with our ability to reach the broad prescriber universe of approximately 9,000 HCPs who see and treat almost 100% of the diagnosed narcolepsy patient opportunity |
| And Sandip, do you want to comment further? Sandip Kapadia We're very pleased last year that we were able to do approximately $100 million share repurchase activities over the last couple of quarters |
| Based on these reasons, along with the vast market opportunity that remains in narcolepsy, we believe that we can continue to grow the franchise for years to come and remain confident that WAKIX represents a $1 billion plus opportunity in adult narcolepsy alone and we are well on our way |
| So we see significant opportunity and room for growth |
| We're generating significant positive cash flow |
| Sandip Kapadia We have good financial strength and flexibility to execute on business development |
| I think that reflects the positive interactions we've had with the agency, the decisions that we've received |
| But Charles, we're extremely pleased with what we're seeing, as I'm hearing from you as well, and we're confident in continued growth in the average number of patients as we move into ‘24 |
| That really affords us the ability to continue to tap into that broad diagnosed patient opportunity as the market allows around the traditional quarterly dynamics that we speak about each earnings call |
| And what that does is that affords us the opportunity to tap into the full diagnosed patient opportunity, both those individuals and healthcare professionals outside the oxybate REMS program, which we continue to see meaningful growth in the number of unique writers every quarter but even within the oxybate REMS enrolled healthcare professionals, even with the availability of generic and once nightly oxybate launches this year, we're seeing meaningful growth in terms of depth of prescribing in that audience |
| The Zynerba acquisition, which closed last October, represented an important step in that direction and was an excellent strategic fit for Harmony, bringing in two late stage development programs focused on orphan rare neuropsychiatric disorders with significant unmet medical needs |
| And I think some of the things that we're seeing Charles is given the unique and meaningfully differentiated product profile, WAKIX has the ability and our sales team has the ability to engage with the broad 9,000 approximate healthcare professionals that see and treat the narcolepsy patients |
| With approximately $426 million in cash, cash equivalents and investments at year end, we are in a solid financial position to execute on BD opportunities, which is a strategic priority for us |
| In conclusion, I am proud of our team's accomplishments in 2023 and what we were able to do to help patients living with narcolepsy, while advancing our development programs in other rare disease patient populations |
| We experienced solid and durable growth in our core commercial business, strong momentum in our clinical development programs and expansion and diversification of our pipeline assets |
| Based on the dedication and commitment across our organization, I am very excited for our opportunities in 2024 as we remain focused on developing and commercializing innovative treatments for patients living with rare neurological diseases who have unmet medical needs |
| 2023 was a strong year of growth for WAKIX and year four of our commercialization in adult narcolepsy |
| The fourth quarter represented the strongest revenue quarter in our history with continued growth and momentum in our underlying business fundamentals and top line performance metrics |
| Jeffrey Dierks We've been extremely pleased with the durable growth that we've seen in the average number of patients on WAKIX |
| Statement |
|---|
| It looks like you're expecting a slowdown in net patient adds each quarter |
| And as we have mentioned previously, more than half of the patients with PWS have excessive daytime sleepiness and almost all of these patients have behavioral disturbances |
| Obviously, in the first quarter, there's usually headwinds regarding gross-to-net pressure and normal things that happen typically in the seasonality that happened |
| For gross to net, I know you said that there will be headwinds in first quarter |
| So you'll see the traditional payer headwinds in the first quarter that impact all brands and specialty products |
| But can you just quantify what you think it will be for the full year? Jeffrey Dayno Sandip? Sandip Kapadia As I mentioned, typically in the first quarter across the industry, there are general headwinds from just higher copay obligations and insurance plans resets in the first quarter |
| You'll see the traditional fewer patient visits associated with chronically managed conditions and diseases in Q3 |
| But were there any changes in the trial design as there originally were, which also caused delays? And then also on the pediatric opportunity, I know you said it's a pretty small opportunity |
| It's important to note that these two symptoms, excessive daytime sleepiness and fatigue are present in approximately 80% to 90% of patients with DM1, and these symptoms are as impactful as a core symptom of myelodonia and progressive muscle weakness |
Please consider a small donation if you think this website provides you with relevant information